Pneumococcal Testing market

Pneumococcal infection is a potentially fatal illness caused by the bacteria pneumococci. Centers for Disease Control and Prevention, it is the leading cause of vaccine-preventable death in adults 65 and older (CDC). Pneumococcal disease, among other things, can cause pneumonia, meningitis, and sepsis.

Pneumococcal disease refers to any infection caused by the bacteria Streptococcus pneumoniae, also known as pneumococci. Infections caused by pneumococcal bacteria can range from ear and sinus infections to pneumonia and bloodstream infections. Pneumococcal disease can be prevented with vaccines. A urine test can assist doctors in making a diagnosis of pneumococcal pneumonia in adults. Ear and sinus infections are typically diagnosed based on history and physical exam findings that support pneumococcal infection. A lumbar puncture is used by doctors to obtain a sample of cerebrospinal fluid.

The pneumococcal testing market is expected to grow at a **% CAGR from 2019 to 2031. The main factors driving the growth of this market are increased awareness of the importance of pneumococcal vaccination and advancements in diagnostic techniques that produce more accurate results. Pneumococcal disease is becoming more common worldwide, particularly in developing countries. Some of the key factors driving the growth of the pneumococcal testing market are increased awareness and the implementation of pneumococcal vaccine programs.

ABBOTT LABORATORIES, BECTON, DICKINSON AND COMPANY, BIOMERIEUX S.A., BIO-RAD LABORATORIES, INC., F. HOFFMANN-LA ROCHE AG, HOLOGIC, INC., MERIDIAN BIOSCIENCE, INC., and QUEST DIAGNOSTICS, INC. are some of the market leaders.